Hangzhou Tigermed Consulting Co., Ltd (HNGZY)

Market Cap	4.75B -6.9%
Revenue (ttm)	1.03B +8.7%
Net Income	111.85M +129.9%
EPS	0.13 +135.5%
Shares Out	n/a
PE Ratio	42.43
Forward PE	26.36
Dividend	0.03 (0.72%)
Ex-Dividend Date	Jun 13, 2025

Volume	300
Open	4.000
Previous Close	4.140
Day's Range	4.000 - 4.000
52-Week Range	4.000 - 4.300
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About HNGZY

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 11,130
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNGZY

Financial Performance

In 2025, HNGZY's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Financial numbers in CNY